Cargando…

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

INTRODUCTION: Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Finn, Richard S, Dering, Judy, Conklin, Dylan, Kalous, Ondrej, Cohen, David J, Desai, Amrita J, Ginther, Charles, Atefi, Mohammad, Chen, Isan, Fowst, Camilla, Los, Gerret, Slamon, Dennis J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790859/ https://www.ncbi.nlm.nih.gov/pubmed/19874578 http://dx.doi.org/10.1186/bcr2419

Ejemplares similares

Cell differentiation and dominant signaling pathway signatures in the molecular classification of human breast cancer cell lines
por: Wilson, CA, et al.
Publicado: (2005)

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
por: Schwartz, G K, et al.
Publicado: (2011)

HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells
por: Wilson, Cindy A, et al.
Publicado: (2005)

PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis
por: LI, CHUNSHENG, et al.
Publicado: (2014)

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
por: Finn, Richard S., et al.
Publicado: (2016)

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
por: Konecny, G E, et al.
Publicado: (2008)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells
por: Kitada, Kunio, et al.
Publicado: (2019)

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors
por: Liu, Minghui, et al.
Publicado: (2016)

CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
por: Schröder, Lisette B. W., et al.
Publicado: (2015)

PD 0332991对人内皮细胞增殖和凋亡的作用
Publicado: (2018)

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
por: Liu, Minghui, et al.
Publicado: (2021)

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer
por: Fejzo, Marlena S., et al.
Publicado: (2013)

FAM117A Is a New Prognostic Marker of Lung Adenocarcinoma and Predicts Sensitivity to PD0332991
por: Wu, Chao, et al.
Publicado: (2022)

Role of Cyclin-Dependent Kinase 1 in Translational Regulation in the M-Phase
por: Kalous, Jaroslav, et al.
Publicado: (2020)

Luminance-polarity distribution across the symmetry axis affects the electrophysiological response to symmetry
por: Wright, Damien, et al.
Publicado: (2018)

Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells
por: Wang, Daguang, et al.
Publicado: (2018)

Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier
por: Chiang, Huai-Chin, et al.
Publicado: (2012)

Clinical evaluation of BCL-2/X(L) levels pre- and post- HER2-targeted therapy
por: Zoeller, Jason J., et al.
Publicado: (2021)

Differentiated microdomains on the luminal surface of the capillary endothelium. I. Preferential distribution of anionic sites
Publicado: (1981)

PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma
por: Barton, Kelly L., et al.
Publicado: (2013)

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
por: Bollard, Julien, et al.
Publicado: (2017)

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Liu, Yu, et al.
Publicado: (2022)

Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer
por: N. Abdalla, Ashraf, et al.
Publicado: (2020)

Retracted: Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition
por: Hamidi, H, et al.
Publicado: (2014)

Human Adult Astrocyte Extracellular Vesicle Transcriptomics Study Identifies Specific RNAs Which Are Preferentially Secreted as EV Luminal Cargo
por: Shanthi, Keerthanaa Balasubramanian, et al.
Publicado: (2023)

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
por: Clark, Amy S., et al.
Publicado: (2023)

Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
por: Hao, Junmei, et al.
Publicado: (2021)

Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens
por: Dai, Liping, et al.
Publicado: (2014)

Recent translational research: microarray expression profiling of breast cancer – beyond classification and prognostic markers?
por: Wilson, Cindy A, et al.
Publicado: (2004)

High phosphorylated cyclin-dependent kinase 2 expression indicates poor prognosis of luminal androgen receptor triple-negative breast cancer: pCDK2 in luminal androgen receptor TNBC
por: Jin, Zining, et al.
Publicado: (2022)

Probing the luminal microenvironment of reconstituted epithelial microtissues
por: Cerchiari, Alec E., et al.
Publicado: (2016)

THE TOTAL LUMINOUS EFFICIENCY OF LUMINOUS BACTERIA
por: Harvey, E. Newton
Publicado: (1925)

Observations on Luminous Animals
por: Macartney, J.
Publicado: (1811)

Observations on Luminous Animals
por: Macartney, J.
Publicado: (1811)

Validation of absolutely quantitated Ki67 and cyclinD1 protein levels for prognosis of Luminal‐like breast cancer patients
por: Yu, Guohua, et al.
Publicado: (2022)

Colour, Luminance and Crowding
por: Jennings, BJ, et al.
Publicado: (2013)

Preferential Cochleotoxicity of Cisplatin
por: Prayuenyong, Pattarawadee, et al.
Publicado: (2021)

Topoisomerase VI is a chirally-selective, preferential DNA decatenase
por: McKie, Shannon J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nndqjfv00ceav43aqjlhfb4m6b